KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 16c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.90), $0.16 better than the analyst estimate of ($1.06).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04